Low-sodium oxybate (Xywav) reduces excessive sleep and daytime naps in idiopathic hypersomnia, with placebo withdrawal worsening sleep duration and symptoms.

Avadel Pharmaceuticals announced that its drug LUMRYZTM received Orphan Drug Designation from the FDA for treating Idiopathic Hypersomnia (IH), a rare sleep disorder. This designation, based on the ...

WEST PALM BEACH, Fla., Sept. 17, 2024 /PRNewswire/ -- The Sleep Consortium, in partnership with a coalition of global sleep-related patient advocacy organizations, proudly announces publication of the ...

DUBLIN, June 05, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that LUMRYZ TM has been ...

Alkermes is transforming into a fully integrated biopharma, leveraging Vibrance-2 results and the Avadel acquisition for competitive advantage in sleep medicine. ALKS’s robust legacy portfolio funds ...

A large Australian study showed atypical depression has distinct genetic, clinical, and treatment-response features. Read more.